Orla Cloak, Ph.D., the newly-appointed CEO of Minaris Advanced Therapies at the Philadelphia Navy Yard, recently discussed the firm’s plans to refine its long-term strategy, writes John George for the Philadelphia Business Journal.
Dr. Cloak joins the company with 20 years of commercial leadership experiences within the life sciences industry.
Minaris Advanced Therapies was established in May 2025 and is the result of New York-based investment firm Altaris’ acquisition of Japan’s Minaris Regenerative Medicine.
Upon its launch in May, Minaris had about 1,400 employees worldwide, including about 800 at its Navy Yard headquarters. However, that overall number of drastically reduced to about 1,100 employees globally.
According to Dr. Cloak, the layoffs were a part of the company’s integration process to combine the two acquisitions.
“It was really about what’s the right size for the organization,” she said.
As part of the company’s effort to refine its long-term vision and business strategy, Dr. Cloak is focused on retaining and developing talent.
“We will grow our workforce as needed to support our clients and expand our capabilities to meet market demand,” she said.
As a scientist by training with a doctorate in microbiology, she was attracted by how Minaris and cell and gene therapy modality is redefining medicine, as well as having an impact on patients’ lives.
Read more about Orla Cloak and Minaris Advanced Therapies in the Philadelphia Business Journal.
_____
